Janssen to Move forward with Clinical Development of LAVA Therapeutics’s Lead Gamma-Delta T-Cell Engager Bispecific Antibody
Autolus Therapeutics to Present Positive Results from its Phase 2 FELIX study in adult r/r B-ALL at ASCO